Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2021 · 10-Q
Revenue$11.23M$11.23M+48.1% vs Q1 2020 Net Income-$637.38K-$637.38KN/M vs Q1 2020 EPS Diluted-$0.04-$0.04N/M vs Q1 2020 Gross Profit$6,124,608+41.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow$1,665,750N/M Free Cash Flowderived$1,645,879N/M Margins · derivedGross margin54.5%−2.7 pt vs Q1 2020
Operating margin-5.7%+24.1 pt vs Q1 2020
Net margin-5.7%+23.4 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end